Alzheimer's disease, a progressive brain disorder caused by the degeneration of cells neurons, is currently ranked the seventh most common cause of death in the U.S., according to the National Institute of Aging. Agitation is one of the most disruptive and burdensome symptoms of dementia due to Alzheimer's disease, as it is associated with greater caregiver stress, increased morbidity and mortality. Otsuka Pharma/Lundbeck's Rexulti is the first and only FDA-approved drug to treat agitation symptoms associated with dementia due to Alzheimer's Disease. Unfortunately, this drug carries a black-box warning for mortality in elderly people.
The stock we are bringing to your attention today is that of a company aiming to capitalize on the substantial unmet medical need in the Alzheimer's disease agitation treatment landscape - Neumora Therapeutics Inc. (NMRA).
For comments and feedback contact: editorial@rttnews.com
June 19, 2026 16:46 ET Major central banks continued to dominate the economic news flow this week too, led by the Federal Reserve, as they announced their latest policy decisions. The Federal Reserve policy session was in focus as it was the first to be led by the new chief Kevin Warsh. In Europe, central banks of the U.K. and Switzerland announced their rate decisions. In Asia, the Bank of Japan drew attention for its policy moves, while data out of China threw some light on the state of the economy.